Skip to main content
placeholder image

64 Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.

Journal Article


Abstract


Publication Date


  • 2022

Citation


  • Wong, K., Sheehan-Dare, G., Nguyen, A., Ho, B., Liu, V., Lee, J., . . . Emmett, L. (2022). 64 Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.. Journal of Clinical Oncology, 40(16_suppl), 3092. doi:10.1200/jco.2022.40.16_suppl.3092

Web Of Science Accession Number


Start Page


  • 3092

End Page


  • 3092

Volume


  • 40

Issue


  • 16_suppl

Abstract


Publication Date


  • 2022

Citation


  • Wong, K., Sheehan-Dare, G., Nguyen, A., Ho, B., Liu, V., Lee, J., . . . Emmett, L. (2022). 64 Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial.. Journal of Clinical Oncology, 40(16_suppl), 3092. doi:10.1200/jco.2022.40.16_suppl.3092

Web Of Science Accession Number


Start Page


  • 3092

End Page


  • 3092

Volume


  • 40

Issue


  • 16_suppl